Intensity Therapeutics, Inc. INTS
2.47 USD -0.07 (-2.76%)
As ofNov 20, 2026, 2:05 PM EST
2.28 Day range 2.48
2.28 52-week range 15.00
- YTD
- -75.90%
- 1 year
- -74.00%
5D +0.10 (+3.37%)
- Market cap
- 8.15M
- EPS (ttm)
- -3.48
- Shares out
- 15.10M
- Forward P/E
- -1.66
- YTD return
- -75.90%
- 1-year return
- -74.00%
- 50-day average
- 2.90
- 200-day average
- 4.10
- Volume
- 50.20K
- Avg volume
- 21.82K
- Open
- 2.39
- Previous close
- 2.54
- Day's range
- 2.28 – 2.48
- 52-week range
- 2.28 – 15.00
- Analysts
- Strong Buy
- Price target
- 10.00 (+304.9%)
Key statistics
- Enterprise value
- 37.55M
- Price / book
- 2.04
- Free cash flow
- 9.66M
- Total cash
- 6.32M
- Total debt
- 151.00K
- Return on equity
- -147.23%
- Short % of float
- 0.48%
Fundamental scorecard
5 of 25 checks passed on INTS’s reported financials
5of 25 checks passed
- Value 1 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
INTS Revenue — quarterly 0
INTS Net income — quarterly -3.54M
INTS EPS — quarterly -1.09
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -0.27 | -0.25 | +0.02 | +7.41% |
| Aug 8, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| Aug 8, 2024 | Jun 1, 2024 | 0.00 | -0.36 | — | — |
| Mar 14, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
| Nov 13, 2023 | Sep 1, 2023 | 0.00 | -0.17 | — | — |
| Nov 13, 2023 | Sep 1, 2023 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 21, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 31, 2024 | HC Wainwright & Co. | init | — | Buy |
| Jul 11, 2024 | Benchmark | reit | Speculative Buy | Speculative Buy |
| May 16, 2024 | Benchmark | reit | Speculative Buy | Speculative Buy |
| Mar 21, 2024 | Benchmark | reit | Speculative Buy | Speculative Buy |
| Nov 14, 2023 | Benchmark | reit | Speculative Buy | Speculative Buy |
About Intensity Therapeutics, Inc.
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs in the United States. Its lead product candidate includes INT230-6, which is in human clinical studies for the treatment of refractory solid tumors, such as soft tissue sarcoma which is in phase 3 trails; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- intensitytherapeutics.com
News
StoneX Maintains Speculative Buy on Intensity Therapeutics, Lowers Price Target to $8
Intensity Therapeutics Q3 2026 Earnings Call Transcript Intensity Therapeutics Q3 EPS $(1.09) Misses $(0.99) Estimate. Cash and Equivalents $8.5M
12 Health Care Stocks Moving In Friday's Pre-Market Session Intensity Therapeutics To Present Data For First Seven Participants In Group A In INVINCIBLE-4 Trial In ePoster By The Swiss Cancer Institute At ESMO 2026 Virtual Congress Platform
Your note
Sign in to keep a note on INTS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| WESOLOWSKI JOHN CPA | Officer | Conversion of Exercise of derivative security | Jun 4, 2024 | 6,691 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Sapient Capital LLC | 6.69% | 1,010,753 | 1.98M | Sep 29, 2024 |
| Vanguard Group Inc | 1.38% | 208,886 | 408.85K | Sep 29, 2024 |
| Brown Advisory Inc. | 0.98% | 148,109 | 289.89K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.43% | 64,349 | 125.95K | Sep 29, 2024 |
| Sigma Planning Corp | 0.32% | 47,744 | 93.45K | Sep 29, 2024 |
| Mesirow Financial Investment Management, Inc. | 0.29% | 44,177 | 86.47K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.11% | 168,299 | 329.41K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.27% | 40,587 | 79.44K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.23% | 34,522 | 67.57K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.13% | 20,123 | 39.39K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.06% | 9,421 | 18.44K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.05% | 8,141 | 15.93K | Oct 30, 2024 |
